查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2005129

急性缺血性腦中風診斷市場：按產品類型、檢測類型、疾病類型、技術和最終用戶分類－2026-2032年全球市場預測

Acute Ischemic Stroke Diagnosis Market by Product Type, Test Type, Disease Type, Technology, End-User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，急性缺血性腦中風診斷市場價值將達到 39.9 億美元，到 2026 年將成長至 42.4 億美元，到 2032 年將達到 64.7 億美元，複合年成長率為 7.13%。

主要市場統計數據
基準年 2025 39.9億美元
預計年份：2026年 42.4億美元
預測年份 2032 64.7億美元
複合年成長率 (%) 7.13%

為了支持策略決策，確定緊急臨床優先事項和技術促進因素，以重組急性缺血性腦中風。

急性缺血性腦中風仍然是全球範圍內導致發病率和死亡率的主要原因之一，因此需要快速、實證的診斷策略來最佳化臨床療效。在時間緊迫的臨床過程中，隨著新的生物標記、先進的影像技術和床邊解決方案的整合，我們的診斷方式也在不斷發展，這些技術能夠縮短診斷時間並實現更精準的干涉。隨著臨床團隊不斷完善分流通訊協定，轉運前意識、院內診斷和介入準備之間的相互作用對於降低殘疾率和改善康復過程至關重要。

探索加速診斷和重塑急性缺血性腦中風治療的關鍵技術進步和護理路徑創新。

急性缺血性腦中風的診斷正經歷著一場變革，這主要得益於技術進步、工作流程的重新設計以及以速度和準確性為優先的新型診療模式。諸如快速CT灌注影像通訊協定和複雜的MRI序列等先進影像技術正日益融入超急性期診療流程，有助於區分缺血半暗帶組織和不可逆損傷區域，從而輔助制定再灌注治療方案。同時，攜帶式影像設備和遠端醫療平台使得在社區和基層醫療機構開展診斷成為可能，遠距專家能夠指導時間緊迫的干涉措施。

本研究評估了關稅制度的變化和跨境貿易的複雜性如何影響急性中風診斷的籌資策略和供應鏈韌性。

關稅政策和跨境貿易趨勢的變化會對用於診斷急性缺血性腦中風的診斷設備和耗材的供應和成本結構產生重大影響。 2025年，不斷上漲的關稅壓力影響了醫療影像設備組件、檢測試劑和專用一次性用品的供應鏈，迫使採購團隊重新評估其供應商關係和籌資策略。因此，各機構紛紛拓展供應管道，並加強關鍵物資的庫存彈性，以避免重症病患的救治工作中斷。

綜合產品、測試、疾病、技術和最終用戶觀點，我們確定了差異化的採用路徑和臨床效用。

從多個細分觀點了解市場，有助於明確不同的臨床和營運需求如何驅動需求和應用模式。按產品類型分類，診斷路徑包括血液生物標記檢測、頸動脈超音波、CT掃描儀和MRI系統等影像學檢查以及腦電圖，每種方法都發揮互補作用，從快速分診到病因分類。按檢測類型分類，臨床工作流程依賴臨床實驗室和代謝指標檢測，其中臨床實驗室還包括基於血液檢測和影像學的評估，以指導急性治療方案的選擇。依疾病類型分類，栓塞性中風、腔隙性梗塞和血栓性中風的診斷重點各不相同，每種疾病在影像學選擇、生物標記解讀和二級預防策略方面都有其獨特的意義。按技術分類，檢測工具涵蓋從基於生物標記的檢測到就地檢驗平台，這些工具在結果出具時間、所需基礎設施和操作人員培訓方面存在差異。根據最終用戶，有關實施和採購的決策由門診手術中心、診斷中心、醫院和診所以及研究實驗室主導，每個機構的病例量、監管限制和臨床期望都各不相同。

檢查基礎設施、臨床通訊協定和實施趨勢的區域差異，以協調不同醫療保健環境中的診斷策略。

區域趨勢對急性缺血性腦中風的診斷技術應用、基礎設施投資和臨床通訊協定製定有顯著影響。在美洲，先進的三級醫療中心和綜合醫療網路往往主導著高階影像設備、移動卒中單元和生物標記研究的應用，而同一區域內的遍遠地區仍然面臨著醫療資源匱乏的挑戰，需要遠距遠端醫療和中心輻射式醫療模式。歐洲、中東和非洲的醫療體系差異顯著。核心都市區醫療機構在以卒中網路為重點的公共衛生舉措的支持下，能夠提供優質的醫療服務，而其他地區的資源限制則促使人們尋求實用且擴充性的診斷解決方案。在亞太地區，醫療基礎設施的快速現代化和影像技術的巨額投資擴大了臨床診療能力，但保險報銷體系和醫護人員配備方面的差異導致了先進診斷技術應用方面的差異。

對整合成像、快速檢測和軟體驅動的工作流程融合的競爭格局進行分析，重新定義了診斷差異化。

急性缺血性腦中風診斷領域的主要企業提供差異化的產品系列，涵蓋影像硬體、臨床檢測、照護現場(POC) 平台和整合軟體解決方案。市場領導者透過軟體功能完善現有影像平台，從而提高工作流程效率和定量解讀能力；而創新型新參與企業則專注於生物標記發現、快速檢測以及用於急診室和院前急救的緊湊型診斷設備。影像設備供應商、檢測開發人員和臨床機構之間的合作日益普遍，從而能夠共同開發整合診斷流程，加速臨床檢驗和應用。

為開發人員和醫療保健領導者提供可操作的策略重點，以加速產品應用並確保永續的臨床和商業性優勢。

產業領導者應採取一系列切實可行的優先事項，在控制營運風險的同時，加速產品在臨床上的應用。首先，透過投資互通性、以使用者為中心的設計以及減少應用障礙的培訓項目，使產品開發與實際臨床工作流程保持一致。其次，優先進行臨床檢驗研究，以證明產品能夠顯著縮短診斷時間並改善治療方案選擇，從而增強對保險公司和醫院的價值提案。第三，透過實現生產和分銷管道多元化以及談判簽訂穩定的契約，確保關鍵組件和試劑的供應，從而解決供應鏈脆弱性問題。

為了得出確切的結論，我們採用了嚴謹的多面向調查方法，結合了臨床證據、專家意見和供應鏈分析。

本調查方法整合了多種途徑，包括臨床文獻回顧、專家訪談、技術評估和供應鏈分析，旨在整體情況診斷環境。證據整合利用同儕審查的臨床研究、指引說明和已發表的技術評估，來評估臨床效用和對工作流程的影響。透過對神經科醫生、急診科醫生、放射科醫生、實驗室主管和採購經理的訪談，確定了實際限制因素和推廣應用促進因素；同時，從供應商描述和產品資料表中獲取了有關設備功能和服務模式的技術背景資訊。

本文總結了決定急性中風診斷有效性和患者預後的臨床、技術和操作因素的匯聚。

總之，急性缺血性腦中風的診斷正處於轉折點，隨著技術創新、臨床流程的重新設計以及供應鏈因素的交匯，臨床實踐正在重塑。快速影像、新型生物標記的應用以及就地檢驗總體上能夠實現更準確、更及時的決策，但區域和政策因素會影響這些技術實施的可行性和速度。積極參與工作流程整合、臨床檢驗和採購彈性建構的相關人員，將更有能力將診斷技術的進步轉化為病患預後的可衡量改善。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章：急性缺血性腦中風診斷市場：依產品類型分類

  • 血液生物標記
  • 頸動脈超音波檢查
  • 診斷影像
    • 電腦斷層掃描（CT）掃描儀
    • 磁振造影系統
  • 腦電圖（EEG）

第9章：依偵測類型分類的急性缺血性腦中風診斷市場

  • 臨床試驗
    • 驗血
    • 影像檢查
  • 代謝指標

第10章：急性缺血性腦中風診斷市場：依疾病類型分類

  • 栓塞
  • 湖相特性
  • 血栓性

第11章：急性缺血性腦中風診斷市場：依技術分類

  • 基於生物標記的檢測
  • 即時檢測

第12章：急性缺血性腦中風診斷市場：依最終用戶分類

  • 門診手術中心
  • 診斷中心
  • 醫院和診所
  • 研究機構

第13章：急性缺血性腦中風診斷市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章：急性缺血性腦中風診斷市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章：急性缺血性腦中風診斷市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第16章：美國急性缺血性腦中風診斷市場

第17章：中國急性缺血性腦中風診斷市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Aidoc Medical Ltd.
  • BIOTRONIK SE & Co KG
  • Boehringer Ingelheim International GmbH
  • Boston Scientific Corporation
  • Canon Medical Systems Corporation
  • F. Hoffmann-La Roche Ltd.
  • Fujifilm Holdings Corporation
  • GE Healthcare Technologies Inc.
  • Hitachi, Ltd.
  • Integral Diagnostics（IDX）Group
  • Johnson & Johnson Services, Inc.
  • Koninklijke Philips NV
  • Mediso Ltd.
  • Medtronic PLC
  • Merck & Co.
  • Neusoft Corporation
  • Nihon Kohden Corporation
  • Planmed Oy
  • Samsung Electronics Co. Ltd.
  • Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • Shimadzu Corporation
  • Shionogi & Co., Ltd.
  • Siemens Healthineers
  • Stryker Corporation
  • Toshiba International Corporation
Product Code: MRR-B16853776EA8

The Acute Ischemic Stroke Diagnosis Market was valued at USD 3.99 billion in 2025 and is projected to grow to USD 4.24 billion in 2026, with a CAGR of 7.13%, reaching USD 6.47 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.99 billion
Estimated Year [2026] USD 4.24 billion
Forecast Year [2032] USD 6.47 billion
CAGR (%) 7.13%

Framing the urgent clinical priorities and technological drivers reshaping acute ischemic stroke diagnosis to inform strategic decision-making

Acute ischemic stroke remains a leading cause of morbidity and mortality worldwide and demands rapid, evidence-based diagnostic strategies to optimize clinical outcomes. The diagnostic landscape is evolving as time-critical pathways integrate novel biomarkers, advanced imaging modalities, and point-of-care solutions that shorten time-to-diagnosis and enable more targeted interventions. As clinical teams refine triage protocols, the interplay between pre-hospital recognition, in-hospital diagnostics, and interventional readiness has become central to reducing disability and improving recovery trajectories.

In the context of rising expectations for personalized care, diagnostic stakeholders must balance speed, accuracy, and resource intensity. Technological advances in imaging and laboratory diagnostics have expanded the tools available to clinicians, but they also introduce complexity in procurement, training, and workflow integration. Consequently, institutional leaders and clinical directors face decisions about investment priorities that directly influence patient throughput, treatment windows, and cross-disciplinary collaboration. The subsequent sections synthesize the key shifts in technology, policy, and practice that are shaping acute ischemic stroke diagnosis and highlight strategic considerations for health systems, device manufacturers, and diagnostic laboratories.

Exploring the pivotal technological advancements and care pathway innovations that are accelerating diagnosis and reshaping acute ischemic stroke management

The landscape of acute ischemic stroke diagnosis is undergoing transformative shifts driven by technological refinement, operational redesign, and emerging care models that prioritize speed and precision. Advanced imaging techniques, such as rapid CT perfusion protocols and enhanced MRI sequences, are increasingly integrated into hyperacute workflows to differentiate penumbral tissue from irreversibly damaged areas, thereby informing reperfusion decisions. At the same time, portable imaging and telemedicine platforms have extended diagnostic reach into community and rural settings, enabling remote expertise to guide time-sensitive interventions.

Concurrently, molecular diagnostics and blood-based biomarkers are moving from research settings toward clinical applicability, offering the potential to stratify etiologies and identify patients unlikely to benefit from certain reperfusion strategies. Point-of-care testing technologies are reducing turnaround times for critical parameters and supporting earlier clinical decision-making in emergency and pre-hospital environments. These technological advances are coupled with care pathway innovations such as direct-to-CT triage, mobile stroke units, and streamlined transfer protocols, all of which seek to compress door-to-needle and door-to-groin puncture intervals. Together, these shifts enhance the precision of diagnosis and expand the possibilities for patient-centered, evidence-based acute stroke care.

Assessing how shifting tariff regimes and cross-border trade complexities have influenced procurement strategies and supply chain resilience in acute stroke diagnostics

Tariff policy changes and cross-border trade dynamics can materially influence the availability and cost structure of diagnostic equipment and consumables that support acute ischemic stroke diagnosis. In 2025, heightened tariff pressures affected the supply chains for medical imaging components, laboratory reagents, and specialized disposables, prompting procurement teams to reassess vendor relationships and sourcing strategies. As a result, organizations sought to diversify supply channels and to increase inventory resilience for critical items to avoid disruptions in hyperacute care delivery.

These shifts prompted healthcare providers and diagnostics suppliers to re-evaluate total landed costs and to explore alternative sourcing arrangements, including regional manufacturing partnerships and consolidated procurement frameworks. Clinicians and administrators had to balance the potential for short-term cost increases against the clinical imperative of maintaining rapid diagnostic throughput, which is directly tied to patient outcomes. In response, some systems prioritized capital investments that reduced dependency on imported consumables, while others negotiated long-term supply contracts to stabilize prices and ensure continuity of care. Overall, tariff-related headwinds encouraged a more strategic approach to supply chain management and accelerated considerations for localized production and redundancy planning.

Integrating product, test, disease, technology, and end-user perspectives to reveal differentiated adoption pathways and clinical utility drivers

Understanding the market through multiple segmentation lenses clarifies how distinct clinical and operational needs drive demand and adoption patterns. Based on product type, diagnostic pathways incorporate blood biomarker assays, carotid ultrasound, diagnostic imaging modalities including computed tomography scanners and MRI systems, and electroencephalography, each serving complementary roles from rapid triage to etiologic classification. Based on test type, the clinical workflow relies on lab tests and metabolic panels, with lab tests further encompassing blood tests and imaging-based assessments that inform acute therapeutic choices. Based on disease type, diagnostic priorities differ for embolic, lacunar, and thrombotic strokes, as each presentation carries unique implications for imaging selection, biomarker interpretation, and secondary prevention strategies. Based on technology, detection tools span biomarker-based assays and point-of-care testing platforms, which vary in turnaround time, required infrastructure, and operator training. Based on end-user, adoption and procurement decisions are driven by ambulatory surgical centers, diagnostic centers, hospitals and clinics, and research laboratories, each with distinct volume profiles, regulatory constraints, and clinical expectations.

By synthesizing these segmentation perspectives, stakeholders can align product development, clinical validation, and commercialization strategies with the specific needs of different user types and disease presentations. For example, solutions optimized for point-of-care use will prioritize rapid turnaround and simplified workflows, whereas imaging investments will focus on throughput, compatibility with stroke protocols, and integration with interventional teams. This multi-dimensional view supports targeted innovation and more effective deployment across diverse clinical settings.

Examining regional variations in infrastructure, clinical protocols, and adoption dynamics to align diagnostic strategies across diverse healthcare environments

Regional dynamics exert a profound influence on diagnostic adoption, infrastructure investment, and clinical protocols for acute ischemic stroke. In the Americas, advanced tertiary centers and integrated health networks often lead in deploying high-end imaging, mobile stroke units, and biomarker research, while rural regions within the same geography continue to face access challenges requiring telemedicine and hub-and-spoke models. In Europe, the Middle East & Africa, healthcare systems vary widely, with pockets of excellence in urban centers supported by public health initiatives that emphasize stroke networks, contrasted with areas where resource constraints necessitate pragmatic, scalable diagnostic solutions. In Asia-Pacific, rapid modernization of healthcare infrastructure and significant investments in imaging have expanded capacity, yet heterogeneity in reimbursement and workforce availability shapes differential uptake of advanced diagnostics.

These regional contrasts influence where vendors prioritize regulatory approvals, localization of service models, and partnerships with health ministries and hospital groups. Moreover, prevalence patterns, emergency medical services maturity, and regional training programs affect the feasibility of implementing advanced diagnostic workflows. Consequently, companies and health systems must craft regionally tailored strategies that consider infrastructure maturity, clinical practice norms, and the pragmatic needs of providers and patients across diverse settings.

Profiling the competitive landscape where integrated imaging, rapid assays, and software-enabled workflows converge to redefine diagnostic differentiation

Key companies competing in acute ischemic stroke diagnostics are advancing differentiated portfolios that span imaging hardware, laboratory assays, point-of-care platforms, and integrated software solutions. Market leaders complement established imaging platforms with software enhancements that improve workflow efficiency and quantitative interpretation, while innovative entrants concentrate on biomarker discovery, rapid assay formats, and compact diagnostic devices intended for emergency and pre-hospital use. Partnerships between imaging vendors, assay developers, and clinical institutions are increasingly common, enabling co-development of integrated diagnostic pathways that accelerate clinical validation and adoption.

Competitive dynamics also reflect a balance between scale and specialization. Large manufacturers leverage global service networks and established installation bases to sell bundled solutions that integrate scanners, informatics, and training. Meanwhile, agile startups often focus on niche performance advantages such as ultra-rapid assays or AI-enhanced image analysis, aiming to prove clinical impact through targeted trials and strategic collaborations. Overall, the competitive landscape rewards interoperability, regulatory foresight, and demonstrable improvements in diagnostic timelines and decision accuracy, creating opportunities for both consolidation and strategic alliances.

Actionable strategic priorities for developers and healthcare leaders to accelerate adoption and secure durable clinical and commercial advantages

Industry leaders should pursue a set of actionable priorities that accelerate clinical impact while managing operational risk. First, align product development with real-world clinical workflows by investing in interoperability, user-centered design, and training programs that reduce adoption friction. Second, prioritize clinical validation studies that demonstrate meaningful reductions in diagnostic time and improvements in treatment selection, thereby strengthening value propositions for payers and hospitals. Third, address supply chain vulnerabilities by diversifying manufacturing and distribution channels and by negotiating stable agreements that preserve access to critical components and reagents.

Furthermore, organizations should engage payer and regulatory stakeholders early to clarify reimbursement pathways and to design studies that meet evidentiary expectations. Strategic collaborations with emergency medical services, regional stroke networks, and academic centers can accelerate adoption and generate robust clinical data. Finally, invest in scalable service models and managed offerings that reduce total cost of ownership for health systems, and consider targeted commercialization strategies that match product tiering to the capacities of different end-users. Taken together, these actions will enhance market relevance while supporting clinicians in delivering faster, more accurate stroke diagnosis.

Describing a rigorous multi-source research approach combining clinical evidence, expert insights, and supply chain analysis to support robust conclusions

The research methodology integrates a multi-source approach combining clinical literature review, expert interviews, technology assessments, and supply chain analysis to produce a holistic view of the diagnostic landscape. Evidence synthesis draws on peer-reviewed clinical studies, guideline statements, and published technology evaluations to assess clinical utility and workflow implications. Interviews with neurologists, emergency physicians, radiologists, laboratory directors, and procurement leaders informed practical constraints and adoption drivers, while vendor briefings and product datasheets provided technical context on device capabilities and service models.

Supply chain and policy analyses relied on customs and trade documentation, procurement tender information, and public sector policy announcements to evaluate factors affecting equipment and reagent availability. Where appropriate, case examples from high-performance stroke centers illustrated best practices in pathway redesign and technology integration. Throughout the methodology, triangulation of multiple information streams ensured that conclusions reflect clinical realities, operational constraints, and technological trajectories relevant to acute ischemic stroke diagnosis.

Summarizing the converging clinical, technological, and operational forces that will determine diagnostic effectiveness and patient outcomes in acute stroke

In conclusion, acute ischemic stroke diagnosis is at an inflection point where technological innovation, pathway redesign, and supply chain considerations converge to reshape clinical practice. Rapid imaging, emergent biomarker applications, and point-of-care testing collectively enable more precise and timely decision-making, while regional and policy factors influence the feasibility and pace of adoption. Stakeholders who proactively address workflow integration, clinical validation, and procurement resilience will be best positioned to translate diagnostic advances into measurable improvements in patient outcomes.

Looking forward, the sustained focus on reducing time-to-treatment, combined with iterative improvements in diagnostic accuracy, will continue to drive investment and collaboration across clinical, commercial, and policy domains. By emphasizing interoperability, evidentiary rigor, and adaptive supply strategies, healthcare providers and industry partners can ensure that the next generation of diagnostic tools delivers both clinical value and operational sustainability for acute ischemic stroke care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Acute Ischemic Stroke Diagnosis Market, by Product Type

  • 8.1. Blood Biomarker
  • 8.2. Carotid Ultrasound
  • 8.3. Diagnostic Imaging
    • 8.3.1. Computed Tomography (CT) Scanner
    • 8.3.2. MRI System
  • 8.4. Electroencephalography

9. Acute Ischemic Stroke Diagnosis Market, by Test Type

  • 9.1. Lab Tests
    • 9.1.1. Blood Test
    • 9.1.2. Imaging Tests
  • 9.2. Metabolic Panel

10. Acute Ischemic Stroke Diagnosis Market, by Disease Type

  • 10.1. Embolic
  • 10.2. Lacunar
  • 10.3. Thrombotic

11. Acute Ischemic Stroke Diagnosis Market, by Technology

  • 11.1. Biomarker-Based Detection
  • 11.2. Point Of Care Testing

12. Acute Ischemic Stroke Diagnosis Market, by End-User

  • 12.1. Ambulatory Surgical Centers
  • 12.2. Diagnostic Centers
  • 12.3. Hospitals & Clinics
  • 12.4. Research Laboratories

13. Acute Ischemic Stroke Diagnosis Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Acute Ischemic Stroke Diagnosis Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Acute Ischemic Stroke Diagnosis Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Acute Ischemic Stroke Diagnosis Market

17. China Acute Ischemic Stroke Diagnosis Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Aidoc Medical Ltd.
  • 18.7. BIOTRONIK SE & Co KG
  • 18.8. Boehringer Ingelheim International GmbH
  • 18.9. Boston Scientific Corporation
  • 18.10. Canon Medical Systems Corporation
  • 18.11. F. Hoffmann-La Roche Ltd.
  • 18.12. Fujifilm Holdings Corporation
  • 18.13. GE Healthcare Technologies Inc.
  • 18.14. Hitachi, Ltd.
  • 18.15. Integral Diagnostics (IDX) Group
  • 18.16. Johnson & Johnson Services, Inc.
  • 18.17. Koninklijke Philips N.V.
  • 18.18. Mediso Ltd.
  • 18.19. Medtronic PLC
  • 18.20. Merck & Co.
  • 18.21. Neusoft Corporation
  • 18.22. Nihon Kohden Corporation
  • 18.23. Planmed Oy
  • 18.24. Samsung Electronics Co. Ltd.
  • 18.25. Shenzhen Mindray Bio-Medical Electronics Co., Ltd.
  • 18.26. Shimadzu Corporation
  • 18.27. Shionogi & Co., Ltd.
  • 18.28. Siemens Healthineers
  • 18.29. Stryker Corporation
  • 18.30. Toshiba International Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD BIOMARKER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY CAROTID ULTRASOUND, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COMPUTED TOMOGRAPHY (CT) SCANNER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY MRI SYSTEM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY ELECTROENCEPHALOGRAPHY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BLOOD TEST, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY IMAGING TESTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY METABOLIC PANEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY EMBOLIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LACUNAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY THROMBOTIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY BIOMARKER-BASED DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY POINT OF CARE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY HOSPITALS & CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 71. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 72. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 74. AMERICAS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 77. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 78. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 80. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. NORTH AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 83. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 86. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 88. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 89. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 90. LATIN AMERICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 96. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 98. EUROPE, MIDDLE EAST & AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 99. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 107. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 110. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 112. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 114. MIDDLE EAST ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 115. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 116. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 117. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 118. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 120. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. AFRICA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 123. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 126. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 127. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 128. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 129. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 130. ASIA-PACIFIC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 132. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 135. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 137. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 139. ASEAN ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 140. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 143. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 144. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 145. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 147. GCC ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 152. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 153. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 155. EUROPEAN UNION ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 156. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 157. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 159. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 160. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 161. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 163. BRICS ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 164. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 167. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 168. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 169. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 170. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 171. G7 ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 172. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 173. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 175. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 177. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 179. NATO ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 180. GLOBAL ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 181. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 182. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 183. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 184. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 186. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 187. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 188. UNITED STATES ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)
  • TABLE 189. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 190. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DIAGNOSTIC IMAGING, 2018-2032 (USD MILLION)
  • TABLE 192. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 193. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY LAB TESTS, 2018-2032 (USD MILLION)
  • TABLE 194. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY DISEASE TYPE, 2018-2032 (USD MILLION)
  • TABLE 195. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 196. CHINA ACUTE ISCHEMIC STROKE DIAGNOSIS MARKET SIZE, BY END-USER, 2018-2032 (USD MILLION)